Literature DB >> 15694752

Familial covariation of the subclinical psychosis phenotype and verbal fluency in the general population.

Lydia Krabbendam1, Inez Myin-Germeys, Manon Hanssen, Jim van Os.   

Abstract

OBJECTIVE: Cognitive impairments may be markers of familial transmission of liability to psychosis. This study examined to what degree the subclinical psychosis phenotype in the general population shows similar familial continuity with cognition, measured with a verbal fluency test, and whether this was similar for men and women.
METHODS: Measures of the subclinical psychosis phenotype and verbal fluency were administered to a general population sample of genetically related individuals (n=425).
RESULTS: In men but not women, higher levels of the subclinical psychosis phenotype were associated with worse verbal fluency performance both within and across relatives.
CONCLUSION: Psychosis and verbal fluency may be more strongly linked in men than in women, and this difference is also expressed at the subclinical level of the phenotype.

Entities:  

Mesh:

Year:  2005        PMID: 15694752     DOI: 10.1016/j.schres.2004.08.009

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  13 in total

1.  Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort study.

Authors:  M D G Dominguez; Marieke Wichers; Roselind Lieb; Hans-Ulrich Wittchen; Jim van Os
Journal:  Schizophr Bull       Date:  2009-05-21       Impact factor: 9.306

2.  Disruptions in White Matter Maturation and Mediation of Cognitive Development in Youths on the Psychosis Spectrum.

Authors:  Catherine E Hegarty; Dietsje D Jolles; Eva Mennigen; Maria Jalbrzikowski; Carrie E Bearden; Katherine H Karlsgodt
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-12-27

3.  Data gathering: biased in psychosis?

Authors:  Frank Van Dael; Dagmar Versmissen; Ilse Janssen; Inez Myin-Germeys; Jim van Os; Lydia Krabbendam
Journal:  Schizophr Bull       Date:  2005-10-27       Impact factor: 9.306

4.  Striatal abnormalities and spontaneous dyskinesias in non-clinical psychosis.

Authors:  Vijay A Mittal; Joseph M Orr; Jessica A Turner; Andrea L Pelletier; Derek J Dean; Jessica Lunsford-Avery; Tina Gupta
Journal:  Schizophr Res       Date:  2013-10-22       Impact factor: 4.939

5.  Cingulo-opercular network efficiency mediates the association between psychotic-like experiences and cognitive ability in the general population.

Authors:  Julia M Sheffield; Sridhar Kandala; Gregory C Burgess; Michael P Harms; Deanna M Barch
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-11

6.  Dermatoglyphic asymmetries and fronto-striatal dysfunction in young adults reporting non-clinical psychosis.

Authors:  V A Mittal; D J Dean; A Pelletier
Journal:  Acta Psychiatr Scand       Date:  2012-04-20       Impact factor: 6.392

7.  Subjective experience of cognitive failures as possible risk factor for negative symptoms of psychosis in the general population.

Authors:  Stefanie Pfeifer; Jim van Os; Manon Hanssen; Philippe Delespaul; Lydia Krabbendam
Journal:  Schizophr Bull       Date:  2008-02-21       Impact factor: 9.306

8.  Speech prosody abnormalities and specific dimensional schizotypy features: are relationships limited to male participants?

Authors:  Jeffrey S Bedwell; Alex S Cohen; Benjamin J Trachik; Andrew E Deptula; Jonathan C Mitchell
Journal:  J Nerv Ment Dis       Date:  2014-10       Impact factor: 2.254

Review 9.  Linking RDoC and HiTOP: A new interface for advancing psychiatric nosology and neuroscience.

Authors:  Giorgia Michelini; Isabella M Palumbo; Colin G DeYoung; Robert D Latzman; Roman Kotov
Journal:  Clin Psychol Rev       Date:  2021-03-24

10.  Relationship of cognitive function in patients with schizophrenia in remission to disability: a cross-sectional study in an Indian sample.

Authors:  Rajeev Krishnadas; Brian P Moore; Ajita Nayak; Ramesh R Patel
Journal:  Ann Gen Psychiatry       Date:  2007-07-30       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.